Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05092360
Title Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab (ARTISTRY-7)
Recruitment Recruiting
Gender female
Phase Phase III
Variant Requirements No
Sponsors Alkermes, Inc.
Indications

ovary epithelial cancer

fallopian tube cancer

peritoneum cancer

Therapies

Pembrolizumab

ALKS 4230

Topotecan

Paclitaxel

Pegylated liposomal-doxorubicin

Gemcitabine

ALKS 4230 + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA | CAN


No variant requirements are available.